Is Biotricity, Inc. overvalued or undervalued?

As of 14 February 2020, Biotricity, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios indicate significant challenges, with a Price to Book Value of -0.44 and an EV to EBITDA of -8.26, reflecting negative financial performance. The company also shows a P/E ratio of NA due to being loss-making, which further complicates its valuation.
In comparison to peers, Biotricity's valuation metrics are concerning. For instance, CareCloud, Inc. is rated "very attractive" with a P/E of 9.67, while Biotricity's P/E stands at -1.16. Other peers like CXApp, Inc. and Intellinetics, Inc. also exhibit risky valuations, but Biotricity's negative ratios suggest it is lagging significantly behind its competitors. Additionally, Biotricity's stock has underperformed relative to the S&P 500 over the past year, with a return of -55.63% compared to the index's 10.26%, reinforcing the notion of overvaluation.